- Soliton is positioning its proprietary technology as a new standard of care in the multimillion-dollar tattoo-removal industry
- The company recently filed a 501(k) with the FDA for its Rapid Acoustic Pulse tattoo-removal device
- Soliton’s cellulite reduction clinical trials have been featured on Yahoo Finance’s First Trade live stream
Medical device company Soliton Inc. (NASDAQ: SOLY) plans to launch its Rapid Acoustic Pulse (RAP) device into the tattoo-removal market, positioning it as the new standard of care. The company also plans to complete its fat and cellulite reduction trials by 2023. The valuable new RAP technology is licensed from the University of Texas on behalf of the MD Anderson Cancer Center. The RAP device is covered by eight patent families representing 38 issued or pending patents worldwide.
Tattoo removal is on the rise, and the surrounding industry is forecast to reach $4.8 billion by 2023. Laser therapy holds 66 percent of the market but is time consuming and costly (http://ibn.fm/8n9rm). Typical laser treatment for tattoo removal results in an 11-16 percent reduction in pigment and requires 10 to 20 visits over a two-year period for the complete removal of the tattoo because of the body’s reaction to the treatment and the need for healing between appointments.
The conventional method is painful, damages the skin and lacks predictable results; the method also costs up to $3,500 or more. When using the RAP device, multiple laser passes can be performed in a single-treatment session. This reduces visits down to two or three for tattoo removal, which also reduces the cost.
In a recent clinical study, 100 percent of the tattoos treated with Soliton RAP achieved 75 percent fading in three or fewer office visits, supporting the company’s claim of being three or more times faster than conventional methods. The RAP device uses very high energy — around 3,000 volts at nearly 3,000 amps — to form acoustic shockwaves 100 times per second. The acoustic waves are virtually painless, do not damage the skin and are divergent, thus eliminating heat. Soliton recently filed for a 501(k) with the FDA for its RAP tattoo-removal device (http://ibn.fm/RKmEt), which is not currently available for sale.
Soliton has a strong commitment to science and is conducting animal and human trials to confirm the safety and efficacy of the technology. The company believes in transparency, and the results of its clinical trials can be found on its website at www.Soliton.com. The technology is currently undergoing fat clinical trials and a cellulite reduction trial.
Soliton recently announced that its manufacturing partner has delivered the first replaceable cartridge targeting cellulite reduction (http://ibn.fm/CSr81). This cartridge delivers the high-powered acoustic pulses at even greater depths than the tattoo-removal cartridge.
“We are very enthusiastic about the flexibility that our interchangeable treatment heads will bring to the practitioners that partner with us for the treatment of cellulite reduction and tattoo removal,” Dr. Chris Capelli, Soliton president, CEO and co-founder, stated in a news release. “Our therapy will be delivered through single-use cartridges that are designed to be used for one patient treatment. Once our device is cleared by the FDA, we expect to deliver a recurring revenue stream and drive top-line growth for the company.”
On May 13, 2019, Soliton was featured on First Trade, the new live-streaming Yahoo Finance show (http://ibn.fm/WP4sg). The focus during the segment was on the newly released cellulite clinical trial data. Soliton is strategically positioned to serve a global market combating cellulite, which is estimated to reach $1.4 billion by 2026.
For more information, visit the company’s website at www.Soliton.com